Canopy Growth Is Closing in on Positive EBITDA. Should You Buy the Stock?

Canopy Growth reported Q1 fiscal 2027 net revenue of $57.4 million, up 13% year over year, while its adjusted EBITDA loss narrowed 59% to $2.3 million and adjusted gross margin expanded 600bps to 31%. Management expects positive adjusted EBITDA in fiscal 2027 as MTL Cannabis integration yields an estimated $7.2 million of annual cost savings, supported by MTL's $60.2 million trailing revenue base. The key risk remains cash generation: free-cash-flow outflow worsened to $18.5 million from $8.3 million, although Canopy held $241.4 million of cash and has debt maturities extended to January 2031.

Analysis

The investable inflection is not adjusted EBITDA itself but whether the acquired cultivation capacity converts into lower unit costs and releases working capital. In Canadian cannabis, EBITDA can improve through overhead cuts while cash burn persists because inventory, excise taxes, receivables, and integration costs absorb liquidity; the market should therefore assign little multiple expansion until two consecutive quarters show operating cash-flow conversion. The longer debt runway reduces near-term solvency pressure but can also delay the discipline that forces a durable capital-allocation reset.

Near term, WEED/CGC can trade higher on any confirmation of breakeven EBITDA in the next two reported quarters, particularly if medical and export mix keeps gross margins above 30%. The more consequential 6-18 month question is whether proprietary flower allows pricing and supply reliability advantages against Canadian licensed producers such as TLRY, OGI, and VFF, rather than simply adding capacity to an oversupplied market. European medical demand is a potential upside asymmetry, but regulatory rollout and reimbursement remain too fragmented to underwrite as a base-case earnings driver.

Consensus may overvalue the optics of a narrow adjusted-EBITDA profit. A modest revenue miss, gross-margin reversal, or another working-capital-driven cash outflow would quickly revive equity-financing risk, especially given cannabis equities' historically high volatility and limited institutional sponsorship. The key falsifier is not EBITDA breakeven: it is positive operating cash flow and declining cash usage without a material increase in receivables or inventory.

Key Decisions for Investors

• Maintain WEED/CGC as a watchlist turnaround rather than initiate a core long before the next two quarterly cash-flow statements; upgrade only if operating cash flow turns positive and gross margin holds above 30%.
• For tactical risk capital, consider a small long CGC/short TLRY pair after confirmed EBITDA positivity: CGC has the clearer self-supply/integration catalyst, while the short hedges broad cannabis-regulatory beta. Target a 15-20% relative move over 3-6 months; exit if CGC cash burn remains elevated or integration savings are deferred.
• Do not chase a headline-driven rally above the post-results range without evidence of cash conversion. Use a stop tied to a renewed quarterly free-cash outflow above roughly $15 million or a material reduction in liquidity, either of which would raise dilution probability.
• Monitor Canadian wholesale flower pricing, European medical shipment growth, and receivables/inventory days at the next earnings release. These are more decision-relevant than adjusted EBITDA and will determine whether margin improvement is structural or accounting/timing-driven.